Liquid biopsies and ctDNA shown to track SCLC progression, with widespread implications for diagnosis and treatment.
First-time genotyping of MPTT points to improved diagnosis, targeted therapies.
As understanding of drug resistance grows, so must therapeutic strategies.
Join Vanderbilt cancer researchers as they present new data on clinical trials.
Expanded screening addresses varying risk factors and could help African Americans.
Interim results suggest advantages over crizotinib for ALK-positive disease.
Initiative will bring telehealth to rural providers and patients.